No abstract available.
Atherosclerosis* ; Homocysteine*

Background: Preeclampsia is a major cause of maternal and perinatal mortality and morbidity, affecting 5 - 6% of all pregnancies. Recently, homocysteine (Hcy), a metabolite of amino acid methionine has been postulated producing oxidative stress, endothelial cell dysfunction, and alterations associated with preeclampsia. It is unclear whether high concentration of circulating Hcy causes preeclampsia, or whether this is a secondary phenomenon of metabolic alterations resulting from the disorder. Objectives: (1) Determining blood Hcy concentration in pregnancies in various severities of preeclampsia. (2) Discover the relationships between serum Hcy and other biological markers in preeclampsia. Subjects and method: This descriptive cross-sectional study consisted of 3 groups of pregnancies admitted to Thanh Nhan Hospital: 24 normal pregnant women, 28 pregnancies with non-serious preeclampsia, and 27 pregnancies with serious preeclampsia. Concentrations of blood Hcy of all participants were assayed by a competition fluorescence immunoassay (FPIA). Results: The mean concentration of serum Hcy during normal pregnancy was 5.2+/-1.0micromol/L compared with 7.1+/-1.8micromol/L among pregnancies with non-serious preeclampsia, and 11.7+/-2.9micromol/L among pregnancies with serious preeclampsia. Serum Hcy increased in pregnancies with renal dysfunction, elevated serum uric acid, and injuries of liver cells. Conclusion: Concentration of the serum Hcy in pregnancies with serious preeclampsia is significantly higher than that of pregnancies with non-serious preeclampsia, and the serum Hcy in pregnancies with non-serious preeclampsia is significantly higher than that of normal pregnancies. There are relationships between elevated serum Hcy in preeclampsia with level of kidney failure, injury of liver and increased levels of serum uric acid.
Homocysteine ; Preeclampsia

68 patients with stroke treated at Hue Central Hospital from March to June 2004. Risk factors as hypertension, smoking were evaluated. Patients had clinical and paraclinical examination such as CT scanning of cerebral skull, blood formula. Blood level of homocystein was estimated: The prevalence of stroke in gender male/female was 1.64/1 with 61.76% men and 38.24 women. Hypertension 85.24%, men/women 1.64/1. Smoke 67.65%. Blood level of homocystein increases in stroke by the rate of 77.94%, as for hemorrhagic stroke was 65.63%, for ischemic stroke was 88.57%. Stroke rate increased by age, especially after 55 years old. A positive correlation between blood level of homocystein and hematocrite was notified
Stroke ; Homocysteine ; blood

Over the last decade there is strong evidence indicating that hyperhomocysteinemia appears to be an important risk factor for vascular diseases, including cerebrovascular disease and myocardial infarction. Several multicenter-randomized trials have demonstrated that it is independent to other well known risk factors such as hypertension, diabetes mellitus, hyperlipidemia and smoking. Given the intense interest of our community concerning the prevention of cerebrovascular diseases we begin to measure homocysteinemia with a simple and accurate technique. The first results of our study raise the exciting possibility that homocysteinemia levels can be normalized by an inexpensive, well tolerated therapy with folate, pyridoxine hydrochloride and cyanocobalamin.
Cerebrovascular Disorders ; Homocysteine

The concentration of blood homocystein (Hcy) in 26 patients with cerebrovascular accident (CVA) was determined preliminarily in Central Hospital in Hue city. 57.69% was the incidence of CVA in male and 42.31% in female patients (in male it was 1.36 fold higher than in female). Hcy concentration increased in 80.77% CVA patient. The rate of increase of blood level of Hcy was 66.67% in brain hemorrhage, 92.86% in brain infarctus. The incidence of CVA enhanced with the age, especially after the age of 55. High blood pressure accounted for 76.92% in CVA. 17/26 (65.38%) was the ratio of tobacco smoler.
Data Collection ; Homocysteine ; Blood ; Stroke

No abstract available.
Folic Acid* ; Homocysteine* ; Methylenetetrahydrofolate Reductase (NADPH2)*

BACKGROUND: The aim of this study was to investigate alterations in homocysteine levels with delays in the initiation time of centrifugation. Attempts were made to improve the processing of samples by analyzing the homocysteine levels of patients from a health promotion center, where delays in the initiation of sample centrifugation were expected because of the nature of the workload and operational procedures. METHODS: Forty healthy adults were selected for the measurement of homocysteine levels. The two samples those were obtained from each individual simultaneously and separately were designated as group A (centrifugation initiation time < or =20 minutes after blood sampling) and group B (> or =2 hours). The degree of deviation from the homocysteine reference interval was also evaluated with samples from 1,134 adults who had medical check-up at a health promotion center from August 1, 2009 to July 31, 2010. RESULTS: The mean serum homocysteine level in group B was significantly higher than that of group A (12.4 vs. 10.6 micromol/L, P<0.0001). Homocysteine level increased with a mean of 19.4% when the initiation of centrifugation was delayed over 2 hours. In the 1,134 adults who had medical check-up, the numbers outside the reference interval were 334 (29.5%). Abnormal samples with homocysteine levels out of the reference interval were reduced to about 7% in July 2011 through improving sample processing to minimize delays in centrifugation initiation time. CONCLUSIONS: Homocysteine levels rapidly increase as blood sample centrifugation is delayed. Therefore, in order to provide accurate test results immediate centrifugation of blood samples is critical.
Adult ; Centrifugation ; Health Promotion ; Homocysteine ; Humans

At the University Medical Center, from August, 2001 to August, 2002, total plasma Homocystein of 31 controls and 50 type 2 diabetes was measured. The mean value of homocystein concentrations in type 2 diabetes is 11.77  4.45 M/l (mean  SD). This is significantly higher than the value of controls (9.93  2.93 M/l (mean  SD)
Homocysteine ; Diabetes Mellitus, Type 2 ; disease ; Plasma

BACKGROUND: Psoriasis is a multifactorial disease associated with an increased risk for metabolic syndrome and cardiovascular diseases. Elevated levels of homocysteine (Hcy) are a marker of cardiovascular risk. Several studies have evaluated the associations between psoriasis and Hcy levels; however, the results remain inconclusive. OBJECTIVE: We performed a systematic review of the literature and a meta-analysis to better understand the relationship between psoriasis and Hcy. METHODS: Five scientific databases (MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science) were searched to identify relevant studies. A review of 307 publications identified 16 studies that directly assessed plasma levels of Hcy in psoriasis patients. RESULTS: A total of 16 studies including 2,091 subjects were included in the meta-analysis. Hcy levels were significantly higher in psoriasis patients relative to healthy controls (weighted mean difference [WMD], 3.30; 95% confidence interval [CI], 1.58∼5.02; I²=82.1%). Subgroup analyses revealed that patients with higher mean psoriasis area severity index (PASI) scores (PASI>10) had significantly higher Hcy levels compared to healthy controls (WMD, 4.17; 95% CI, 1.18∼7.16; I²=88.3%), whereas patients with lower mean PASI scores (PASI ≤10) had not (WMD, 0.76; 95% CI, −1.84∼3.35; I²=72.2%). CONCLUSION: This meta-analysis found that psoriasis patients, in particular those with PASI >10, had significantly higher Hcy levels compared to healthy controls. Further research is needed to determine the association between Hcy levels and psoriasis severity.
Cardiovascular Diseases ; Homocysteine ; Humans ; Plasma ; Psoriasis

Homocysteine (Hcy) is an intermediate metabolite of methionine metabolism. Hyperhomocysteinemia (HHcy) is defined as a condition characterized by plasma Hcy level above 16 μmol/L which can result from abnormal Hcy metabolism. HHcy has been confirmed to be related to cardio-cerebrovascular disease, peripheral vascular disorders, neurodegenerative diseases, diabetes, pregnancy-induced hypertension syndrome, liver cirrhosis and kidney diseases. In this review, we summarize the correlation between HHcy and kidney diseases. Elucidating the role of HHcy in kidney diseases may provide a new strategy to prevent and treat kidney diseases.
Homocysteine ; Humans ; Hyperhomocysteinemia ; complications ; Kidney Diseases ; complications